Sökning: onr:"swepub:oai:lup.lub.lu.se:92f957ca-71cc-4c81-8317-049d931d98cc" >
Efficacy of RG1-VLP...
Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses
-
Schellenbacher, Christina (författare)
-
Kwak, Kihyuck (författare)
-
Fink, Dieter (författare)
-
visa fler...
-
Shafti-Keramat, Saeed (författare)
-
Huber, Bettina (författare)
-
Jindra, Christoph (författare)
-
- Faust, Helena (författare)
- Lund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups
-
- Dillner, Joakim (författare)
- Karolinska Institutet
-
Roden, Richard B. S. (författare)
-
Kirnbauer, Reinhard (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2013
- 2013
- Engelska.
-
Ingår i: Journal of Investigative Dermatology. - : Elsevier BV. - 1523-1747 .- 0022-202X. ; 133:12, s. 2706-2713
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
http://www.jidonline...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-assembled from major capsid protein L1, afford type-restricted protection against HPV types 16/18/6/11 (or 16/18 for the bivalent vaccine), which cause 70% of cervical cancers (CxCas) and 90% of genital warts. However, they do not protect against less prevalent high-risk (HR) types causing 30% of CxCa, or cutaneous HPV. In contrast, vaccination with the minor capsid protein L2 induces low-level immunity to type-common epitopes. Chimeric RG1-VLP presenting HPV16 L2 amino acids 17-36 (RG1 epitope) within the DE-surface loop of HPV16 L1 induced cross-neutralizing antisera. We hypothesized that RG1-VLP vaccination protects against a large spectrum of mucosal and cutaneous HPV infections in vivo. Immunization with RG1-VLP adjuvanted with human-applicable alum-MPL (aluminum hydroxide plus 3-O-desacyl-4'-monophosphoryl lipid A) induced robust L2 antibodies (ELISA titers 2,500-12,500), which (cross-)neutralized mucosal HR HPV16/18/45/37/33/52/58/35/39/51/59/68/73/26/69/34/70, low-risk HPV6/11/32/40, and cutaneous HPV2/27/3/76 (titers 25-1,000) using native virion-or pseudovirion (PsV)-based assays, and a vigorous cytotoxic T lymphocyte response by enzyme-linked immunospot. In vivo, mice were efficiently protected against experimental vaginal challenge with mucosal HR PsV types HPV16/18/45/31/33/52/58/35/39/51/59/68/56/73/26/53/66/34 and low-risk HPV6/43/44. Enduring protection was demonstrated 1 year after vaccination. RG1-VLP is a promising next-generation vaccine with broad efficacy against all relevant mucosal and also cutaneous HPV types.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Schellenbacher, ...
-
Kwak, Kihyuck
-
Fink, Dieter
-
Shafti-Keramat, ...
-
Huber, Bettina
-
Jindra, Christop ...
-
visa fler...
-
Faust, Helena
-
Dillner, Joakim
-
Roden, Richard B ...
-
Kirnbauer, Reinh ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Dermatologi och ...
- Artiklar i publikationen
-
Journal of Inves ...
- Av lärosätet
-
Lunds universitet
-
Karolinska Institutet